Bodei, Lisa
Michael Tuttle, R.
Grewal, Ravinder K.
Mauguen, Audrey
Augensen, Finn
Abusamra, Murad
Mahajan, Sonia
Jayaprakasam, Vetri Sudar
Osborne, Joseph R.
Haque, Sofia
Wong, Bernadette Z. Y.
Ghossein, Ronald A.
Fagin, James
Schӧder, Heiko
Ho, Alan
Humm, John L.
Larson, Steven M. http://orcid.org/0000-0002-6111-7507
Article History
First Online: 15 September 2023
Declarations
:
: Not applicable to this Editorial
: Not applicable
: Steven M. Larson, Audrey Mauguen, Alan Ho, Ravinder Grewal, and John Humm are co-inventors of provisional patent for Soothsayer: Number 63/193,700 filed on 5/27/21; conversion deadline: 5/27/22 “Soothsayer,” filed by Office of Technology Development, MSK. L Bodei reports consulting (uncompensated) for Novartis, Ipsen, ITM, Point Biopharma, RayzeBio, Precirix, and Great Point Partners, and institutional research funding from Novartis. SM Larson reports receiving commercial research grants from Y-mAbs Therapeutics, Inc., Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; holding ownership interest/equity in Elucida Oncology, Inc.; and holding stock in ImaginAb, Inc., and Y-mAbs Therapeutics. SML is the inventor of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., Elucida Oncology, Inc., and Y-mAbs Therapeutics, Inc. SML serves or has served as a consultant both compensated and uncompensated to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., Exini, Inc., and Janssen Pharmaceuticals, Inc. See ExternalRef removed<u>=</u> for further details.